Target intelligence / Profile preview

Small proline-rich protein 2G (SPRR2G)

Target
SPRR2G
Molecular classification
Other (structural protein, cornified envelope protein, keratinocyte differentiation protein)[1][2][5]
01

Overview

Small proline-rich protein 2G is a structural protein expressed in keratinocytes, where it contributes to the formation of the cornified envelope underlying the plasma membrane during terminal differentiation. It is cross-linked to membrane proteins by transglutaminase, supporting the physical barrier properties of the skin[1][2][5]. SPRR2G and other small proline-rich proteins play a role in epidermal homeostasis, keratinization, and response to external insults[4][6]. The SPRR gene family is upregulated in response to stress, inflammation, and skin pathology, and participates in keratinocyte differentiation. SPRR2G is regulated via upstream factors including estradiol and may interact with p73 and RBM38 regulatory loops, relevant to inflammation and tumor suppression in the context of related family members[3][6]. There is no evidence for direct modulation by therapeutic agents or validated clinical biomarker usage. SPRR2G is primarily a structural constituent of the epidermis, not a canonical pharmacologic target like a receptor or enzyme, but rather contributes to barrier formation and is implicated in skin differentiation and inflammatory responses[1][5][6].

Other names
Small proline rich protein 2GSPR-2GSPRR2GSPR2G
02

Mechanism of action

Not applicable; no known drugs target SPRR2G directly.

03

Biological functions

Keratinocyte differentiation[1][6]Formation of insoluble cross-linked envelope in epidermis[1][2][5]Structural constituent of skin epidermis[4]Upstream or within response to estradiol[1][4]
04

Disease associations

Inflammation (gene family contributes to barrier function and is implicated in chronic inflammation via related pathways)[3][6]Skin barrier function and disorders (e.g., psoriasis; SPRR and LCE genes are upregulated in inflammatory skin conditions such as psoriasiform dermatitis)[6]Potential association with cancer (modulated in neoplastic tissues, but not a driver)[3]
05

Safety considerations

None known for direct targeting; as a structural protein, therapeutic modulation could theoretically impact skin integrity/barrier function, but SPRR2G is not used as a drug target[1][5][6].
06

Biomarkers

No validated clinical biomarkers for SPRR2G itself; family members may be altered in inflammatory skin conditions and cancer[6]. Not established as a patient selection or efficacy biomarker.

Beyond the preview

Go deeper on Small proline-rich protein 2G (SPRR2G).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Small proline-rich protein 2G (SPRR2G).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call